Recent Advances in Canadian Neuropsychopharmacology

Selected Proceedings of the 2nd Annual Meeting of the Canadian College of Neuropsychopharmacology, Hamilton, Ont., April 1979

Recent Advances in Canadian Neuropsychopharmacology

Editors
Paul Grof and Bishan Saxena, Hamilton, Ont.

42 figures and 40 tables, 1980

The 2nd Annual Meeting of the Canadian College of Neuropsychopharmacology was held at McMaster University Medical Center, Hamilton, Ontario, under the auspices of The Hamilton Psychiatric Hospital and Department of Psychiatry, McMaster University, Hamilton, Ontario.

National Library of Medicine, Cataloging in Publication
Recent advances in Canadian neuropsychopharmacology: selected proceedings of the 2nd annual meeting of Canadian College of Neuropsychopharmacology held at McMaster University Medical Centre, Hamilton, Ontario, April 1979.
Meeting held under the auspices of the Hamilton Psychiatry Hospital and Dept. of Psychiatry, McMaster University, Hamilton, Ontario.
I. Psychopharmacology-congresses I. Grof, P., ed. II. Saxena, Bishan, ed. III. Canadian College of Neuropsychopharmacology IV. Hamilton Psychiatric Hospital V. McMaster University. Dept. of Psychiatry VI. Title VII. Series
QV 77 R295 1979
ISBN 3-8055-1459-X

Drug Dosage
The authors and publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved.
Contents

Lapierre, Y.D.: Preface ................................................................. VII
Grof, P. and Saxena, B.: Introduction ........................................ IX

Chapter 1: Pharmacology

Baker, G.B.; Coutts, R.T.; Benderly, A.; McKim, H.R., and Dewhurst, W.G.:
Fluorinated amphetamines: Effects on release of putative neurotransmitter amines
in the striatum of the rat. ............................................................................................1
McKim, H.R.; Calverley, D.G.; Philips, S.R.; Baker, G.B., and Dewhurst, W.G.:
The effects of tranylcypromine on the levels of some cerebral amines in rat
diencephalon. ............................................................................................................ 7
Prell, G.D. and Mazurkiewicz-Kwilecki, I.M.: Chronic alcohol treatment and brain
histamine levels. ......................................................................................................... 14
Rastogi, R.B.; Lapierre, Y.D., and Singhal, R.L.: Some behavioural and neuropharma-
cological aspects of fenobam: A new antianxiety drug. ........................................ 26
Tepperman, F.S.; Hirst, M., and Gowdey, C.W.: Temperature responses in the rat with
repeated intraventricular met-enkephalin injections. ............................................. 36

Chapter 2: Neuroendocrinology

Grota, L.J.; Holloway, W.R.; Tsui, H.W., and Brown, G.M.: Melatonin and diurnal
rhythmicity. ................................................................................................................... 43
Mishra, R.K. and Cleghorn, J.M.: Dopamine receptors in the central nervous system:
Basic and clinical neuroendocrine studies. ............................................................ 50
Rathbone, M.P.; Carlone, R.L.; Van der Jagt, R.H.C., and Ganagarajah, M.: Putative
neurotrophic factors in brain tissue-novel neuromodulators? ................................. 68
Seggie, J.: Limbic system and psychoneuroendocrinology: An animal analogue of the
neuroendocrine strategy for investigating psychiatric disturbances. ......................... 85

Chapter 3: Clinical Psychopharmacology

Anath, J.: Psychotropic drug hazards to the fetus: Prevention and new directions for
research. ...................................................................................................................... 99
Amin, M.M.; Khalid, R., and Khan, P.: Imipramine and viloxazine plasma levels and their relevance to antidepressant response. ................................................................. 112
MacCrimmon, D.J. and Saxena, B.: Intramuscular neuroleptics in schizophrenia: Clinical efficacy and side-effect. .................................................................................. 131
Young, S.N.; Gibson, C.J., and Gauthier, S.: Possible mechanisms for the therapeutic window in the antidepressant action of tryptophan. ........................................... 147

Chapter 4: Lithium-Clinical and Experimental Aspects
Viol, G.W.: Lithium and the kidney: A concise review.................................................. 159
McClure, D.J.; Pecknold, J.C., and Tanaka, Y.: Serum levels of rubidium as a predictor of lithium response in manic-depressive patients. ........................................ 166
Tyrer, S.P.; Kalvar, M.; Shopsin, B., and Grof, P.: Prediction of lithium dose requirement: Comparison of renal lithium clearance and serum lithium estimation. ................. 172
Werstiuk, E.S.; Rathbone, M.P.; Grof, P.; Clark, N., and Daigle, L.: Membrane transport abnormalities in affective disorders................................................................. 182

Chapter 5: Teaching of Psychopharmacology
Pinard, G.: The teaching of psychopharmacology: A problem. ................................. 195
Gagnon, A.: The teaching of psychopharmacology: A resident's point of view. ........... 197
Garcin, F.: Teaching and training models in psychopharmacology: The pharmacologist's point of view................................................................. 201
Garfinkel, P.E.; Cameron, P., and Kingstone, E.: Psychopharmacology education in psychiatry................................................................. 221

Preface
The Canadian College of Neuropsychopharmacology was a dream until two short years ago. This second annual scientific meeting is a realization of this dream for most of us. The bringing together of basic scientists and clinical investigators, the sharing of their ideas, their difficulties and their approaches is illustrated by the contents of the proceedings recorded in this monograph.
Canada is a large country with a small population. The geographical distances which separate us are great. They are all too often paralleled by the distances separating scientists and clinicians and even by those separating workers within the same discipline.
Mental functioning is the resultant of an innumerable number of complex of electrical and chemical reactions of an equally large number of
neurological subsystems. The final results of these interactions is human thought and emotion. The complexity of the involved processes supersedes the capability of understanding of any single person. It is only through combined and collaborative efforts of all associated disciplines that it will be possible to eventually undertake to comprehend the most simple of these mechanisms to ultimately unlock the mystery of human thought. Animal models will always be part of our working tools but, no matter how complex a model we develop, the ultimate model is the patient. The sick person, with the complexities of intrapsychic, interpersonal and social influences resulting in an interaction of combined chemical and other physiological processes remains the objective of our combined efforts. A forum such as the CCNP is necessary for scientific minds of different expertise to gather and permit cross-fertilization of knowledge to reach out to the sick and allow them to enjoy the benefits of normality.

Yvon D. Lapierre
President
Canadian College of Neuropsychopharmacology

INTRODUCTION

In May 1977 a preliminary meeting was held in Toronto to consider founding the Canadian College of Neuropsychopharmacology. While less than three years have elapsed, the growth of the College has been most encouraging: it has quadrupled its membership, has achieved incorporation as a scientific organization and holds annual scientific meetings. The second annual meeting was held at McMaster University Medical Centre, Hamilton, in April 1979, and brought together nearly 200 participants from Canada and Northern United States. This book contains selected proceedings of this encounter. The major objectives of the College are: to promote neuropsychopharmacological research and treatment; to provide a forum for discussion of ideas and findings from clinical and basic researchers in neuropsychopharmacology; to facilitate the development of neuropsychopharmacology at the national and international level; and finally, to serve as a liason to education institutions, industry, government, public organizations and to related scientific bodies. Hopefully, the second annual meeting has contributed to reaching these goals.

The interdisciplinary nature of the College is reflected in the broad scope of selected papers published in this book. Research reports in this volume reflect active research life and many ongoing
studies at various Canadian institutions.

It has been a rewarding experience for both of us to receive contributions from our esteemed colleagues involved in both clinical and basic science research. Of the thirty-nine presentations made at the second annual meeting of CCNP in Hamilton, a representative selection of manuscripts have come together in this book. For most manuscripts the editorial adjustments were minor. However, the decision made at a later stage to publish this book by the off-camera method necessitated some substantial re-arrangements. To avoid an additional delay, those manuscripts which were retyped and proofread by the authors were not further edited, although some additional modifications could have been beneficial. To all our contributors, busy with their practice, research and other duties, we both would like to express our special thanks.

On behalf of the local organizing committee, we wish to acknowledge generous support provided by the Department of Psychiatry, McMaster University and by the Hamilton Psychiatric Hospital, as well as the contributions by various pharmaceutical companies. This support made it possible to organize the second annual meeting and to publish this volume.

Hamilton, April 1980

PAUL GROF and BISHAN SAXENA
Editors